Now live: European new issue coverage and historical data, for free. → Explore All Content & Delivery Channels
Log In
No results found for "".

Deal Details

C/PIndustryStatusTicker(s)Issuer(s)Size(m)TranchesRegionDate
HYC
HLTH
PRCD
ALMSM
Almirall SA€300
1EMEA
Sep 15, 2021
currency
EUR
size (m)
300.000
maturity
Sep 30, 2026
type
Fixed
tenor
5.000
call
2
registration
144A/Reg S
benchmark
-
ranking
Sr. Unsecured
moody's
Ba3
s&p
BB-
fitch
-
size description
-
re-open/tap
No
ipt
mid 2s
ipt-pxd
-
guidance
2.25-2.50%
spread
276
coupon
2.125%
spread set
-
price
100.00000
yield
2.125%
book size (m)
-
peak book (m)
-
x-covered
-
book attrition
-
nic
-
left lead
active leads
joint leads
passive leads
-
co-managers
-
coordinating managers
-
book size (m)
-
peak book (m)
-
x-covered
-
book attrition
-
nic
-
left lead
active leads
joint leads
passive leads
-
co-managers
-
coordinating managers
-
Tranche Comments
Redemption: 2023-09-30; Registration: 144A/Reg S;
Deal Comments
09/15/2021 (ALMSM) Almirall SA EUR300m (up from EUR250m) 144A/Reg S sr notes due 09/30/26 (5y). NC2 (09/30/23) (MWC B+50bp), then at 101.063, 100.531, 100. Equity claw: 2y 40% at 102.125. Ba3/BB- (stable/stable). Via BNP/JPM (B&D) jt glocos/BBVA/BofA/Caixa/Santander jt books. No reg rights. List lux. NY law. Pays March 15 and Sept 15, starting 03/15/22. Settles 09/22 (T+5). Reg S ISIN: XS238816245. IPT: mid 2s.Px talk: 2.25%-2.50%. Launched: EUR300m at 2.125%. Priced: 2.125% at 100. +276bp vs OBL 0% 10/09/26. Did investor call at 11am UKT 09/13 (virtual 1x1s 09/13-15). Books closed at 12pm UKT 09/15. Recommitments were due by 1pm UKT 09/15 UK afternoon. UOP: to repay its EUR250m 0.25% cvt notes due 12/14/21, and GCP (EUR50m upsize for GCP). Biz: a publicly listed pharmaceutical company that researches, develops, produces and markets a fairly diversified portfolio of in-house developed drugs and in-licensed drugs in therapeutic areas including dermatology, respiratory, gastrointestinal and pain relief. HQ: Barcelona, Spain.

Commentary

Explore all other Commentary & Deal Flow

Deal Flow

Explore all other Commentary & Deal Flow
We use functional cookies to make this site work properly and marketing cookies to personalize content. By continuing or clicking "Ok", you consent to our use of cookies. See our Cookie Policy for more information.
By continuing, you agree to FINSIGHT's Terms of Use and Privacy Policy.